You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

606 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade
Intent: Curative
Jun 2022
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab - First-line Treatment of Advanced Gastric, Esophageal, and Esophagogastric Junction Adenocarcinoma
Apr 2023
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Oct 2021
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Adjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - Adjuvant Treatment for Renal Cell Carcinoma
Mar 2023
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Locally Recurrent Unresectable or Metastatic Triple Negative Breast Cancer
Sep 2023
Document
Guidelines and Advice
Status: Current
ID: GL 1-25
Version: N/A
Mar 2023
Document

Pages